Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 12 entries
Sorted by: Best Match Show Resources per page
Regulation of cytotoxic T-cell responses by p53 in cancer.

Translational cancer research

Braun MW, Iwakuma T.
PMID: 28944167
Transl Cancer Res. 2016 Dec;5(6):692-697. doi: 10.21037/tcr.2016.11.76.

An intriguing aspect of the tumor suppressor p53 is its ability to communicate to the adaptive immune system and control the cytotoxic T-lymphocyte (CTL) response to cancer cells. Wild-type p53 (wtp53) communicates with CTLs through proteins involved in the...

Cite
Braun MW, Iwakuma T. Regulation of cytotoxic T-cell responses by p53 in cancer. Transl Cancer Res. 2016;5(6):692-697doi: 10.21037/tcr.2016.11.76.
Braun, M. W., & Iwakuma, T. (2016). Regulation of cytotoxic T-cell responses by p53 in cancer. Translational cancer research, 5(6), 692-697. https://doi.org/10.21037/tcr.2016.11.76
Braun, Mitchell W, and Iwakuma, Tomoo. "Regulation of cytotoxic T-cell responses by p53 in cancer." Translational cancer research vol. 5,6 (2016): 692-697. doi: https://doi.org/10.21037/tcr.2016.11.76
Braun MW, Iwakuma T. Regulation of cytotoxic T-cell responses by p53 in cancer. Transl Cancer Res. 2016 Dec;5(6):692-697. doi: 10.21037/tcr.2016.11.76. PMID: 28944167; PMCID: PMC5607642.
Copy Download .nbib Format: NLM
Targeting Oncogenic Mutant p53 for Cancer Therapy.

Frontiers in oncology

Parrales A, Iwakuma T.
PMID: 26732534
Front Oncol. 2015 Dec 21;5:288. doi: 10.3389/fonc.2015.00288. eCollection 2015.

Among genetic alterations in human cancers, mutations in the tumor suppressor p53 gene are the most common, occurring in over 50% of human cancers. The majority of p53 mutations are missense mutations and result in the accumulation of dysfunctional...

Cite
Parrales A, Iwakuma T. Targeting Oncogenic Mutant p53 for Cancer Therapy. Front Oncol. 2015;5:288doi: 10.3389/fonc.2015.00288.
Parrales, A., & Iwakuma, T. (2015). Targeting Oncogenic Mutant p53 for Cancer Therapy. Frontiers in oncology, 5288. https://doi.org/10.3389/fonc.2015.00288
Parrales, Alejandro, and Iwakuma, Tomoo. "Targeting Oncogenic Mutant p53 for Cancer Therapy." Frontiers in oncology vol. 5 (2015): 288. doi: https://doi.org/10.3389/fonc.2015.00288
Parrales A, Iwakuma T. Targeting Oncogenic Mutant p53 for Cancer Therapy. Front Oncol. 2015 Dec 21;5:288. doi: 10.3389/fonc.2015.00288. eCollection 2015. PMID: 26732534; PMCID: PMC4685147.
Copy Download .nbib Format: NLM
Roles of p53 in extrinsic factor-induced liver carcinogenesis.

Hepatoma research

Link T, Iwakuma T.
PMID: 30123836
Hepatoma Res. 2017;3:95-104. doi: 10.20517/2394-5079.2017.07. Epub 2017 Jun 06.

Liver cancer remains one of the most common human cancers with a high mortality rate. Therapies for hepatocellular carcinoma (HCC) remain ineffective, due to the heterogeneity of HCC with regard to both the etiology and mutation spectrum, as well...

Cite
Link T, Iwakuma T. Roles of p53 in extrinsic factor-induced liver carcinogenesis. Hepatoma Res. 2017;3:95-104doi: 10.20517/2394-5079.2017.07.
Link, T., & Iwakuma, T. (2017). Roles of p53 in extrinsic factor-induced liver carcinogenesis. Hepatoma research, 395-104. https://doi.org/10.20517/2394-5079.2017.07
Link, Tim, and Iwakuma, Tomoo. "Roles of p53 in extrinsic factor-induced liver carcinogenesis." Hepatoma research vol. 3 (2017): 95-104. doi: https://doi.org/10.20517/2394-5079.2017.07
Link T, Iwakuma T. Roles of p53 in extrinsic factor-induced liver carcinogenesis. Hepatoma Res. 2017;3:95-104. doi: 10.20517/2394-5079.2017.07. Epub 2017 Jun 06. PMID: 30123836; PMCID: PMC6097626.
Copy Download .nbib Format: NLM
MTBP inhibits the Erk1/2-Elk-1 signaling in hepatocellular carcinoma.

Oncotarget

Ranjan A, Iyer SV, Ward C, Link T, Diaz FJ, Dhar A, Tawfik OW, Weinman SA, Azuma Y, Izumi T, Iwakuma T.
PMID: 29765550
Oncotarget. 2018 Apr 20;9(30):21429-21443. doi: 10.18632/oncotarget.25117. eCollection 2018 Apr 20.

Hepatocellular carcinoma (HCC) is one of the most common cancers worldwide, and the prognosis of HCC patients, especially those with metastasis, remains extremely poor. This is partly due to unclear molecular mechanisms underlying HCC metastasis. Our previous study indicates...

Cite
Ranjan A, Iyer SV, Ward C, et al. MTBP inhibits the Erk1/2-Elk-1 signaling in hepatocellular carcinoma. Oncotarget. 2018;9(30):21429-21443doi: 10.18632/oncotarget.25117.
Ranjan, A., Iyer, S. V., Ward, C., Link, T., Diaz, F. J., Dhar, A., Tawfik, O. W., Weinman, S. A., Azuma, Y., Izumi, T., & Iwakuma, T. (2018). MTBP inhibits the Erk1/2-Elk-1 signaling in hepatocellular carcinoma. Oncotarget, 9(30), 21429-21443. https://doi.org/10.18632/oncotarget.25117
Ranjan, Atul, et al. "MTBP inhibits the Erk1/2-Elk-1 signaling in hepatocellular carcinoma." Oncotarget vol. 9,30 (2018): 21429-21443. doi: https://doi.org/10.18632/oncotarget.25117
Ranjan A, Iyer SV, Ward C, Link T, Diaz FJ, Dhar A, Tawfik OW, Weinman SA, Azuma Y, Izumi T, Iwakuma T. MTBP inhibits the Erk1/2-Elk-1 signaling in hepatocellular carcinoma. Oncotarget. 2018 Apr 20;9(30):21429-21443. doi: 10.18632/oncotarget.25117. eCollection 2018 Apr 20. PMID: 29765550; PMCID: PMC5940416.
Copy Download .nbib Format: NLM
DNAJA1 promotes cancer metastasis through interaction with mutant p53.

Oncogene

Kaida A, Yamamoto S, Parrales A, Young ED, Ranjan A, Alalem MA, Morita KI, Oikawa Y, Harada H, Ikeda T, Thomas SM, Diaz FJ, Iwakuma T.
PMID: 34183772
Oncogene. 2021 Aug;40(31):5013-5025. doi: 10.1038/s41388-021-01921-3. Epub 2021 Jun 28.

Accumulation of mutant p53 (mutp53) is crucial for its oncogenic gain of function activity. DNAJA1, a member of J-domain containing proteins or heat shock protein 40, is shown to prevent unfolded mutp53 from proteasomal degradation. However, the biological function...

Cite
Kaida A, Yamamoto S, Parrales A, et al. DNAJA1 promotes cancer metastasis through interaction with mutant p53. Oncogene. 2021;40(31):5013-5025doi: 10.1038/s41388-021-01921-3.
Kaida, A., Yamamoto, S., Parrales, A., Young, E. D., Ranjan, A., Alalem, M. A., Morita, K. I., Oikawa, Y., Harada, H., Ikeda, T., Thomas, S. M., Diaz, F. J., & Iwakuma, T. (2021). DNAJA1 promotes cancer metastasis through interaction with mutant p53. Oncogene, 40(31), 5013-5025. https://doi.org/10.1038/s41388-021-01921-3
Kaida, Atsushi, et al. "DNAJA1 promotes cancer metastasis through interaction with mutant p53." Oncogene vol. 40,31 (2021): 5013-5025. doi: https://doi.org/10.1038/s41388-021-01921-3
Kaida A, Yamamoto S, Parrales A, Young ED, Ranjan A, Alalem MA, Morita KI, Oikawa Y, Harada H, Ikeda T, Thomas SM, Diaz FJ, Iwakuma T. DNAJA1 promotes cancer metastasis through interaction with mutant p53. Oncogene. 2021 Aug;40(31):5013-5025. doi: 10.1038/s41388-021-01921-3. Epub 2021 Jun 28. PMID: 34183772.
Copy Download .nbib Format: NLM
Regulators of Oncogenic Mutant TP53 Gain of Function.

Cancers

Yamamoto S, Iwakuma T.
PMID: 30577483
Cancers (Basel). 2018 Dec 20;11(1). doi: 10.3390/cancers11010004.

The tumor suppressor p53 (TP53) is the most frequently mutated human gene. Mutations in TP53 not only disrupt its tumor suppressor function, but also endow oncogenic gain-of-function (GOF) activities in a manner independent of wild-type TP53 (wtp53). Mutant TP53...

Cite
Yamamoto S, Iwakuma T. Regulators of Oncogenic Mutant TP53 Gain of Function. Cancers (Basel). 2018;11(1)doi: 10.3390/cancers11010004.
Yamamoto, S., & Iwakuma, T. (2018). Regulators of Oncogenic Mutant TP53 Gain of Function. Cancers, 11(1), . https://doi.org/10.3390/cancers11010004
Yamamoto, Satomi, and Iwakuma, Tomoo. "Regulators of Oncogenic Mutant TP53 Gain of Function." Cancers vol. 11,1 (2018). doi: https://doi.org/10.3390/cancers11010004
Yamamoto S, Iwakuma T. Regulators of Oncogenic Mutant TP53 Gain of Function. Cancers (Basel). 2018 Dec 20;11(1). doi: 10.3390/cancers11010004. PMID: 30577483; PMCID: PMC6356290.
Copy Download .nbib Format: NLM
Unsaturated fatty acids regulate stemness of ovarian cancer cells through NF-κB.

Stem cell investigation

Parrales A, Ranjan A, Iwakuma T.
PMID: 28607923
Stem Cell Investig. 2017 Jun 03;4:49. doi: 10.21037/sci.2017.05.07. eCollection 2017.

No abstract available.

Cite
Parrales A, Ranjan A, Iwakuma T. Unsaturated fatty acids regulate stemness of ovarian cancer cells through NF-κB. Stem Cell Investig. 2017;4:49doi: 10.21037/sci.2017.05.07.
Parrales, A., Ranjan, A., & Iwakuma, T. (2017). Unsaturated fatty acids regulate stemness of ovarian cancer cells through NF-κB. Stem cell investigation, 449. https://doi.org/10.21037/sci.2017.05.07
Parrales, Alejandro, et al. "Unsaturated fatty acids regulate stemness of ovarian cancer cells through NF-κB." Stem cell investigation vol. 4 (2017): 49. doi: https://doi.org/10.21037/sci.2017.05.07
Parrales A, Ranjan A, Iwakuma T. Unsaturated fatty acids regulate stemness of ovarian cancer cells through NF-κB. Stem Cell Investig. 2017 Jun 03;4:49. doi: 10.21037/sci.2017.05.07. eCollection 2017. PMID: 28607923; PMCID: PMC5460094.
Copy Download .nbib Format: NLM
Murine double minute 2, a potential p53-independent regulator of liver cancer metastasis.

Hepatoma research

Ranjan A, Bera K, Iwakuma T.
PMID: 28944296
Hepatoma Res. 2016;2:114-121. doi: 10.20517/2394-5079.2015.67. Epub 2016 May 06.

Hepatocellular carcinoma (HCC) has emerged as one of the most commonly diagnosed forms of human cancer; yet, the mechanisms underlying HCC progression remain unclear. Unlike other cancers, systematic chemotherapy is not effective for HCC patients, while surgical resection and...

Cite
Ranjan A, Bera K, Iwakuma T. Murine double minute 2, a potential p53-independent regulator of liver cancer metastasis. Hepatoma Res. 2016;2:114-121doi: 10.20517/2394-5079.2015.67.
Ranjan, A., Bera, K., & Iwakuma, T. (2016). Murine double minute 2, a potential p53-independent regulator of liver cancer metastasis. Hepatoma research, 2114-121. https://doi.org/10.20517/2394-5079.2015.67
Ranjan, Atul, et al. "Murine double minute 2, a potential p53-independent regulator of liver cancer metastasis." Hepatoma research vol. 2 (2016): 114-121. doi: https://doi.org/10.20517/2394-5079.2015.67
Ranjan A, Bera K, Iwakuma T. Murine double minute 2, a potential p53-independent regulator of liver cancer metastasis. Hepatoma Res. 2016;2:114-121. doi: 10.20517/2394-5079.2015.67. Epub 2016 May 06. PMID: 28944296; PMCID: PMC5609474.
Copy Download .nbib Format: NLM
RIPK1-TRAF2 interplay on the TNF/NF-κB signaling, cell death, and cancer development in the liver.

Translational cancer research

Yamamoto S, Iwakuma T.
PMID: 30123738
Transl Cancer Res. 2017 May;6:94-109. doi: 10.21037/tcr.2017.04.01.

No abstract available.

Cite
Yamamoto S, Iwakuma T. RIPK1-TRAF2 interplay on the TNF/NF-κB signaling, cell death, and cancer development in the liver. Transl Cancer Res. 2017;6:94-109doi: 10.21037/tcr.2017.04.01.
Yamamoto, S., & Iwakuma, T. (2017). RIPK1-TRAF2 interplay on the TNF/NF-κB signaling, cell death, and cancer development in the liver. Translational cancer research, 694-109. https://doi.org/10.21037/tcr.2017.04.01
Yamamoto, Satomi, and Iwakuma, Tomoo. "RIPK1-TRAF2 interplay on the TNF/NF-κB signaling, cell death, and cancer development in the liver." Translational cancer research vol. 6 (2017): 94-109. doi: https://doi.org/10.21037/tcr.2017.04.01
Yamamoto S, Iwakuma T. RIPK1-TRAF2 interplay on the TNF/NF-κB signaling, cell death, and cancer development in the liver. Transl Cancer Res. 2017 May;6:94-109. doi: 10.21037/tcr.2017.04.01. PMID: 30123738; PMCID: PMC6097634.
Copy Download .nbib Format: NLM
Regulators of Oncogenic Mutant TP53 Gain of Function.

Cancers

Yamamoto S, Iwakuma T.
PMID: 30577483
Cancers (Basel). 2018 Dec 20;11(1). doi: 10.3390/cancers11010004.

The tumor suppressor p53 (TP53) is the most frequently mutated human gene. Mutations in TP53 not only disrupt its tumor suppressor function, but also endow oncogenic gain-of-function (GOF) activities in a manner independent of wild-type TP53 (wtp53). Mutant TP53...

Cite
Yamamoto S, Iwakuma T. Regulators of Oncogenic Mutant TP53 Gain of Function. Cancers (Basel). 2018;11(1)doi: 10.3390/cancers11010004.
Yamamoto, S., & Iwakuma, T. (2018). Regulators of Oncogenic Mutant TP53 Gain of Function. Cancers, 11(1), . https://doi.org/10.3390/cancers11010004
Yamamoto, Satomi, and Iwakuma, Tomoo. "Regulators of Oncogenic Mutant TP53 Gain of Function." Cancers vol. 11,1 (2018). doi: https://doi.org/10.3390/cancers11010004
Yamamoto S, Iwakuma T. Regulators of Oncogenic Mutant TP53 Gain of Function. Cancers (Basel). 2018 Dec 20;11(1). doi: 10.3390/cancers11010004. PMID: 30577483; PMCID: PMC6356290.
Copy Download .nbib Format: NLM
DNAJA1 promotes cancer metastasis through interaction with mutant p53.

Oncogene

Kaida A, Yamamoto S, Parrales A, Young ED, Ranjan A, Alalem MA, Morita KI, Oikawa Y, Harada H, Ikeda T, Thomas SM, Diaz FJ, Iwakuma T.
PMID: 34183772
Oncogene. 2021 Aug;40(31):5013-5025. doi: 10.1038/s41388-021-01921-3. Epub 2021 Jun 28.

Accumulation of mutant p53 (mutp53) is crucial for its oncogenic gain of function activity. DNAJA1, a member of J-domain containing proteins or heat shock protein 40, is shown to prevent unfolded mutp53 from proteasomal degradation. However, the biological function...

Cite
Kaida A, Yamamoto S, Parrales A, et al. DNAJA1 promotes cancer metastasis through interaction with mutant p53. Oncogene. 2021;40(31):5013-5025doi: 10.1038/s41388-021-01921-3.
Kaida, A., Yamamoto, S., Parrales, A., Young, E. D., Ranjan, A., Alalem, M. A., Morita, K. I., Oikawa, Y., Harada, H., Ikeda, T., Thomas, S. M., Diaz, F. J., & Iwakuma, T. (2021). DNAJA1 promotes cancer metastasis through interaction with mutant p53. Oncogene, 40(31), 5013-5025. https://doi.org/10.1038/s41388-021-01921-3
Kaida, Atsushi, et al. "DNAJA1 promotes cancer metastasis through interaction with mutant p53." Oncogene vol. 40,31 (2021): 5013-5025. doi: https://doi.org/10.1038/s41388-021-01921-3
Kaida A, Yamamoto S, Parrales A, Young ED, Ranjan A, Alalem MA, Morita KI, Oikawa Y, Harada H, Ikeda T, Thomas SM, Diaz FJ, Iwakuma T. DNAJA1 promotes cancer metastasis through interaction with mutant p53. Oncogene. 2021 Aug;40(31):5013-5025. doi: 10.1038/s41388-021-01921-3. Epub 2021 Jun 28. PMID: 34183772.
Copy Download .nbib Format: NLM
MTBP inhibits the Erk1/2-Elk-1 signaling in hepatocellular carcinoma.

Oncotarget

Ranjan A, Iyer SV, Ward C, Link T, Diaz FJ, Dhar A, Tawfik OW, Weinman SA, Azuma Y, Izumi T, Iwakuma T.
PMID: 29765550
Oncotarget. 2018 Apr 20;9(30):21429-21443. doi: 10.18632/oncotarget.25117. eCollection 2018 Apr 20.

Hepatocellular carcinoma (HCC) is one of the most common cancers worldwide, and the prognosis of HCC patients, especially those with metastasis, remains extremely poor. This is partly due to unclear molecular mechanisms underlying HCC metastasis. Our previous study indicates...

Cite
Ranjan A, Iyer SV, Ward C, et al. MTBP inhibits the Erk1/2-Elk-1 signaling in hepatocellular carcinoma. Oncotarget. 2018;9(30):21429-21443doi: 10.18632/oncotarget.25117.
Ranjan, A., Iyer, S. V., Ward, C., Link, T., Diaz, F. J., Dhar, A., Tawfik, O. W., Weinman, S. A., Azuma, Y., Izumi, T., & Iwakuma, T. (2018). MTBP inhibits the Erk1/2-Elk-1 signaling in hepatocellular carcinoma. Oncotarget, 9(30), 21429-21443. https://doi.org/10.18632/oncotarget.25117
Ranjan, Atul, et al. "MTBP inhibits the Erk1/2-Elk-1 signaling in hepatocellular carcinoma." Oncotarget vol. 9,30 (2018): 21429-21443. doi: https://doi.org/10.18632/oncotarget.25117
Ranjan A, Iyer SV, Ward C, Link T, Diaz FJ, Dhar A, Tawfik OW, Weinman SA, Azuma Y, Izumi T, Iwakuma T. MTBP inhibits the Erk1/2-Elk-1 signaling in hepatocellular carcinoma. Oncotarget. 2018 Apr 20;9(30):21429-21443. doi: 10.18632/oncotarget.25117. eCollection 2018 Apr 20. PMID: 29765550; PMCID: PMC5940416.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 12 entries